This technology is an orally-administered engineered probiotic that can be used to screen for and treat colorectal cancer.
The current standard of care for colorectal cancer screening is a colonoscopy. While effective at detecting cancer, this procedure is time-consuming, inconvenient for patients, and costly for healthcare providers. Additionally, there are risks associated with the procedure and the anesthesia required for it. Since early detection and intervention is key in treating colorectal cancer, an easier, non-invasive screening method could increase patient compliance and improve patient outcomes.
This technology is an engineered probiotic that can be used for non-invasive screening and treatment of colorectal cancer. The probiotics selectively colonize tumor tissues and can be engineered to secrete urine-detectable screening molecules for tumor discovery, or immunotherapeutics for tumor reduction. This technology is orally-delivered and provides in situ reduction of tumor burden.
This technology has been validated in mouse models.
Patent pending
IR CU22290
Licensing Contact: Cynthia Lang